Current Report Filing (8-k)
March 27 2017 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2017
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 266-3500
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
e) Adoption of 2017 Bonus Program
On March 22, 2017,
the Board approved the 2017 Bonus Program. The 2017 Bonus Program provides Sunesiss executive officers and other eligible employees the opportunity to earn bonuses based on the level of achievement by Sunesis of certain corporate objectives,
or the Corporate Objectives, and by each participant of certain individual objectives, or the Individual Objectives, from January 1, 2017 through December 31, 2017.
The Board has approved the Corporate Objectives and assigned a weighting to each objective. The Compensation Committee of the Board, or the Committee, will
set the Individual Objectives of the chief executive officer, as well as the Individual Objectives of the remaining executive officer participants based on the recommendations of the chief executive officer. The Individual Objectives of
non-executive participants will be set by each participants immediate supervisor.
Each eligible participant in the 2017 Bonus Program may receive a
bonus in an amount up to a specified percentage of such participants annual base salary earned in 2017, or the Bonus Targets; provided, that the Committee may, in its sole discretion, pay all or any portion of an earned bonus to any
participant in shares of common stock granted under the 2011 Equity Incentive Plan. Under the 2017 Bonus Program, the Bonus Targets range from 30.0% to 55.0% of a participants 2017 base salary for vice president level employees and above.
Bonus Targets for participants will be correspondingly adjusted downward in the event the Corporate Objectives are deemed by the Committee to have not been fully achieved. The Committee also has the right, in its sole discretion, to adjust the Bonus
Target of any participant upward in the event of over-achievement of the Corporate Objectives as determined by the Committee. The Committee has set the Bonus Targets for each named executive officer as follows:
|
|
|
|
|
Named Executive Officer
|
|
Bonus
Target
Percentage
|
|
Daniel N. Swisher, Jr.
Chief Executive Officer and President
|
|
|
55.0
|
%
|
Eric H. Bjerkholt
Executive Vice President, Corporate Development and Finance, Chief
Financial Officer and Corporate Secretary
|
|
|
40.0
|
%
|
The Committee will determine the degree to which the Corporate Objectives have been met after considering any
analyses and recommendations of management. Based on such determination, the Committee will adjust these Bonus Targets accordingly.
The Committee will
also determine the level of achievement of the Individual Objectives by the chief executive officer based on its evaluation of the chief executive officers achievements and for other executive officer participants based on the recommendations
of the chief executive officer. The level of achievement of Individual Objectives by non-executive participants will be determined by the Committee based on recommendations of an executive committee designated by the Committee.
There is no set formula for determining the bonus amount under the 2017 Bonus Program based on the achievement of the Corporate and Individual Objectives.
Rather, the Committee will exercise its discretion in determining the bonus amount actually earned by each participant. Awards under the 2017 Bonus Program are expected to occur in the first quarter of 2018. A participant must remain an employee on
the payment date under the 2017 Bonus Program to be eligible to earn a bonus.
The description of the 2017 Bonus Program contained herein does not purport
to be complete and is qualified in its entirety by reference to the 2017 Bonus Program, a copy of which is attached hereto as Exhibit 10.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
10.1
|
|
Sunesis Pharmaceuticals, Inc. 2017 Bonus Program
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
|
|
|
|
Dated: March 27, 2017
|
|
|
|
By:
|
|
/s/ Eric H. Bjerkholt
|
|
|
|
|
|
|
Eric H. Bjerkholt
|
|
|
|
|
|
|
Executive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
10.1
|
|
Sunesis Pharmaceuticals, Inc. 2017 Bonus Program
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024